Privia Health Group, Inc. (PRVA)
NASDAQ: PRVA · IEX Real-Time Price · USD
19.17
+0.07 (0.37%)
At close: Jul 19, 2024, 4:00 PM
19.19
+0.02 (0.10%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Privia Health Group Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Privia Health Group stock have an average target of 24.09, with a low estimate of 19 and a high estimate of 30. The average target predicts an increase of 25.67% from the current stock price of 19.17.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PRVA stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 4 | 4 | 4 |
| Buy | 8 | 6 | 5 | 6 | 6 | 5 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $23 → $20 | Buy | Maintains | $23 → $20 | +4.33% | Jul 9, 2024 |
| Baird | Baird | Buy Initiates $23 | Buy | Initiates | $23 | +19.98% | May 30, 2024 |
| Barclays | Barclays | Hold Maintains $22 → $19 | Hold | Maintains | $22 → $19 | -0.89% | May 20, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $28 → $24 | Strong Buy | Maintains | $28 → $24 | +25.20% | May 15, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $37 → $26 | Strong Buy | Maintains | $37 → $26 | +35.63% | May 10, 2024 |
Financial Forecast
Revenue This Year
2.91B
from 1.66B
Increased by 75.72%
Revenue Next Year
3.27B
from 2.91B
Increased by 12.36%
EPS This Year
0.19
from 0.19
Decreased by -0.24%
EPS Next Year
0.29
from 0.19
Increased by 55.61%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 3.0B | 3.5B | 4.0B | 2.8B | 3.3B |
| Avg | 2.9B | 3.3B | 3.7B | 2.6B | 3.0B |
| Low | 2.8B | 3.1B | 3.4B | 2.4B | 2.6B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 83.9% | 20.1% | 23.3% | -25.2% | 28.5% |
| Avg | 75.7% | 12.4% | 14.4% | -30.7% | 15.3% |
| Low | 67.4% | 5.2% | 5.3% | -36.7% | 1.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 0.27 | 0.43 | 0.56 |
| Avg | 0.19 | 0.29 | 0.36 |
| Low | 0.07 | 0.16 | 0.24 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 43.7% | 127.1% | 88.7% |
| Avg | -0.2% | 55.6% | 22.0% |
| Low | -63.9% | -17.3% | -20.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.